Perrigo Company plc $PRGO Shares Sold by Yelin Lapidot Holdings Management Ltd.

Yelin Lapidot Holdings Management Ltd. decreased its stake in Perrigo Company plc (NYSE:PRGO) by 36.2% in the 1st quarter, Holdings Channel reports. The firm owned 170,000 shares of the company’s stock after selling 96,539 shares during the quarter. Yelin Lapidot Holdings Management Ltd.’s holdings in Perrigo were worth $1,826,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PRGO. Geneos Wealth Management Inc. lifted its position in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the period. Kestra Investment Management LLC grew its holdings in Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Perrigo by 116.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after buying an additional 1,014 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Perrigo in the 4th quarter worth about $28,000. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Stock Down 0.3%

Shares of NYSE:PRGO opened at $9.93 on Monday. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The company has a market capitalization of $1.37 billion, a P/E ratio of -0.76, a P/E/G ratio of 1.18 and a beta of 0.51. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.43. The stock’s fifty day simple moving average is $11.01 and its 200-day simple moving average is $12.21.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the business posted $0.60 EPS. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts forecast that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were issued a dividend of $0.29 per share. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 11.7%. Perrigo’s payout ratio is -8.85%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Perrigo has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.